Exploring immunogenicity and safety after a homologous booster dose of SARS-CoV-2 recombinant spike protein vaccine

By | December 29, 2021
Research suggests that a single booster dose of NVX-CoV2373 given approximately six months after the primary series induced significant increases in humoral antibodies, while also exhibiting an acceptable safety profile.